World's first generic to leading GnRH analogue with controlled release
Xbrane is pioneering high demand biosimilars.
OUTPERFORMING INDUSTRY STANDARDS BY DEVELOPING BIOSIMILARS WITH NEXT GENERATION TECHNOLOGY
Enabling access to critical medication for life critical diseases
Investors
Latest News
-
Xbrane Biopharma AB: Xbrane deltar på Carnegie Nordic HealthCare Day i New York, 5 december
Read more >> -
Xbrane Biopharma AB: Xbrane attends Carnegie Nordic HealthCare Day in New York, 5 December
Read more >> -
Xbrane bekräftar order av Spherotide till ett värde av 8,5 MSEK och över 10 000 doser sålda
Read more >> -
Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold
Read more >> -
Xbrane Biopharma releases interim report for the period April - June 2017
Read more >>
Events
-
09 Jan 2017
J.P. Morgan 35th Annual Healthcare Conference, January 9-12
Read more >>
X
